Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compound that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to the prevention and treatment of Alzheimer's disease.
1. A method of treating age-related macular degeneration, comprising administering to a human subject in need thereof a therapeutically effective amount of a compound of formula IV,
or a pharmaceutically acceptable salt thereof,
wherein:
aa 1 is valine, lysine, serine, alanine, isoleucine, histidine, or O-benzylserine, and
aa 2 is valine, lysine, serine, alanine, isoleucine, histidine, O-benzylserine, or is absent.
2. The method of claim 1 , wherein the compound is a compound of Formula V:
or a pharmaceutically acceptable salt thereof, wherein aa 1 is valine, lysine, serine, alanine, isoleucine, histidine, or O-benzylserine.
3. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt or any of the foregoing.
4. The method of claim 1 , wherein the compound is:
or a pharmaceutically acceptable salt or any of the foregoing.
5. The method of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
6. The method of claim 1 , wherein the therapeutically effective amount of the compound is about 5 to about 500 mg.
7. The method of claim 5 , wherein the therapeutically effective amount of the compound is about 5 to about 500 mg.
8. The method of claim 1 , wherein the therapeutically effective amount of the compound is administered once or twice daily.
9. The method of claim 5 , wherein the therapeutically effective amount of the compound is administered once or twice daily.
10. The method of claim 1 , wherein the therapeutically effective amount of the compound is administered orally.
11. The method of claim 5 , wherein the therapeutically effective amount of the compound is administered orally.